Mechanistic Phase II Clinical Trial of Metformin in Pulmonary Arterial Hypertension

BACKGROUND: Metabolic dysfunction is highly prevalent in pulmonary arterial hypertension (PAH) and likely contributes to both pulmonary vascular disease and right ventricular (RV) failure in part because of increased oxidant stress. Currently, there is no cure for PAH and human studies of metabolic...

Descripción completa

Detalles Bibliográficos
Autores principales: Brittain, Evan L., Niswender, Kevin, Agrawal, Vineet, Chen, Xinping, Fan, Run, Pugh, Meredith E., Rice, Todd W., Robbins, Ivan M., Song, Haocan, Thompson, Christopher, Ye, Fei, Yu, Chang, Zhu, He, West, James, Newman, John H., Hemnes, Anna R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763730/
https://www.ncbi.nlm.nih.gov/pubmed/33167773
http://dx.doi.org/10.1161/JAHA.120.018349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763730/
https://www.ncbi.nlm.nih.gov/pubmed/33167773
http://dx.doi.org/10.1161/JAHA.120.018349

Ejemplares similares